Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 10/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14983420 | 0.82 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL14983415 | 0.81 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL14983408 | 0.73 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL6942099 | 0.71 | MKNK2 (0.40) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL31289390 | 0.71 | HPRT1 (0.42) | ALDH1A1 | |
| SCHEMBL14983422 | 0.70 | FGFR1 (0.41) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL14983412 | 0.67 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL16949944 | 0.64 | ADORA2A (0.37) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL6948090 | 0.64 | ADORA2A (0.41) | ADORA2AADORA1ADORA2BHTTKDM4E | |
| SCHEMBL7078191 | 0.63 | NT5E (0.34) | ADORA2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-9139592-B2 | Modulators of Nrf2 and uses thereof | TRT PHARMA INC. (CA) | 2015-09-22 | — | — | US | disclosed |
| US-9139592-B2 | Modulators of Nrf2 and uses thereof | TRT PHARMA INC. (CA) | 2015-09-22 | — | — | US | disclosed |
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2013-05-30 | — | — | US | disclosed |
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | TRT PHARMA INC. (CA) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137694-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | KEAP1, TXNRD1, NFE2L2 | PI4KA 1826/4885PI4K2B 1290/4885PI4K2A 1526/4885 |
| US-20160083388-A1 | NOVEL MODULATORS OF NRF2 AND USES THEREOF | KEAP1, TXNRD1, NFE2L2 | PI4KA 1826/4885PI4K2B 1290/4885PI4K2A 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.